Membrane and device for treating hemolytic events
AssigneeGambro Lundia AB
InventorsMarkus Storr, Bernd Krause, Michael Hulko, Oliver Amon
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a hemodialysis membrane for the treatment of hemolytic events, especially acute episodes of hemolysis which lead to elevated levels of plasma free hemoglobin. The present disclosure further relates to methods of removing hemoglobin from the blood of patients undergoing a hemolytic event. The treatment and method encompasses using a hemodialysis membrane which is characterized in that it comprises at least one hydrophobic polymer and at least one hydrophilic polymer and in that it has a MWRO of between 15 and 20 kD and a MWCO of between 170-320 kD, or, in the alternative, has a MWRO of between 9 and 14 kD and a MWCO of between 55 kD and 130 kD.
Claims19
A method of removing cell-free plasma hemoglobin from blood of a patient, said method comprising the steps of
- a. withdrawing and passing blood from the patient, the blood comprising a cell-free plasma hemoglobin concentration of above 0.5 g/L in a continuous flow into contact with one face of a semipermeable polymeric hollow-fiber membrane having a MWRO of between 9.0 and 20 kD and a MWCO of between 55-320 kD as determined by dextran sieving before blood contact of the membrane,
- b. simultaneously passing dialysate solution in a continuous flow on the opposite face of the membrane to the side of the membrane in contact with the blood, and
- c. returning the blood into the patient,
- wherein the method reduces cell-free plasma hemoglobin concentration to below about 0.1 g/L.
A method of treating hemolysis in a patient by removing cell-free plasma hemoglobin from blood of the patient, said method comprising the steps of
- a. withdrawing and passing the blood from the patient in a continuous flow into contact with one face of a membrane, wherein the cell-free plasma hemoglobin concentration in the blood of the patient is above 0.5 g/L,
- b. simultaneously passing dialysate solution in a continuous flow on an opposite face of the hemodialysis membrane to the side of the membrane in contact with the blood, and
- c. returning the blood into the patient,
- d. wherein the membrane is characterized in that it comprises at least one hydrophobic polymer and at least one hydrophilic polymer and in that it has a MWRO of between 9.0 and 20 kD and a MWCO of between 55-320 kD as determined by dextran sieving before blood contact of the membrane,
- wherein the method reduces cell-free plasma hemoglobin concentration to below about 0.1 g/L.
Dependencies are inferred from the claim text.